The European Union (EU)-wide Task Force on Availability of Authorised Medicines (TF AAM) has targeted a number of priority actions to be taken over the next two years to prevent, identify and manage medicines supply shortages.
The task force has published its programme of works for the next two years. Among the priority actions identified is a review of existing procedures for withdrawals of medicines to include the requirement for a transition period to allow better planning.
The group, which has been established by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA), will also look at accelerated procedures of mutual recognition so that marketing authorisations for medicinal products can be extended to countries where companies would not normally seek authorisation. The use of multilingual packaging is also being facilitated so that medicines can be transferred easily between countries to address national shortages.
As the international supply of medical isotopes continues to be a concerning issue, the task force plans to specifically target this area by promoting work-sharing and reducing authorisation timetables.
A dedicated task force is to be established by the end of 2020 to specifically identify and address the availability of paediatric formulations across the EU.